Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bonding over biologics
May 2019
SHARING OPTIONS:

SAN DIEGO, CAMBRIDGE, Mass., & BEIJING—Clinical-stage biopharmaceutical company Ambrx Inc. and BeiGene Ltd. recently announced a global research and development collaboration aiming to develop and commercialize next-generation biologics drugs. Per the terms of the deal, BeiGene will pay Ambrx $10 million up front to fund initial discovery and research activities, with additional upfront payments of up to $19 million if BeiGene chooses to launch additional programs. In addition, Ambrx stands to receive up to an aggregate of $446 million for all programs in the form of development, regulatory and sales-based milestone payments, as well as tiered royalties on resulting product sales. BeiGene will hold worldwide rights to develop and commercialize and products created under this collaboration.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.